Trial · NCT06625814
A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)
NCT06625814, Phase 1, Completed, Merck Sharp & Dohme LLC
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028). Trials, record NCT06625814. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06625814
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)
- NCT number
- NCT06625814
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 28 participants, actual
- Lead sponsor
- Merck Sharp & Dohme LLC
- Conditions
- Healthy
- Interventions
- Levothyroxine, Enlicitide Decanoate
- First posted
- 2024-10-03
- Last updated
- 2024-10-03
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Area under the Concentration-Time Curve from Time 0 to 48 hours (AUC0-48hrs) of Levothyroxine (total T4) | At designated timepoints (up to approximately 48 hours postdose) | Blood samples will be collected to determine the AUC0-48hr of Levothyroxine (T4). |
| Primary | Maximum Plasma Concentration (Cmax) of Levothyroxine (total T4) | At designated timepoints (up to approximately 48 hours postdose) | Blood samples will be collected to determine the Cmax of Levothyroxine (T4). |
| Primary | Time to Maximum Plasma Concentration (Tmax) of Levothyroxine (total T4) | At designated timepoints (up to approximately 48 hours postdose) | Blood samples will be collected to determine the Tmax of Levothyroxine (T4). |
| Primary | Area under the Concentration-Time Curve from Time 0 to 48 hours (AUC0-48hrs) of Triiodothyronine (total T3) | At designated timepoints (up to approximately 48 hours postdose) | Blood samples will be collected to determine the AUC0-48hr of triiodothyronine (T3). |
| Primary | Maximum Plasma Concentration (Cmax) of Triiodothyronine (total T3) | At designated timepoints (up to approximately 48 hours postdose) | Blood samples will be collected to determine the Cmax of triiodothyronine (T3). |
| Primary | Time to Maximum Plasma Concentration (Tmax) of Triiodothyronine (total T3) | At designated timepoints (up to approximately 48 hours postdose) | Blood samples will be collected to determine the Tmax of triiodothyronine (T3). |
| Secondary | Number of Participants Who Experience a Treatment-Emergent Adverse Event (TEAE) | Up to approximately 7 weeks | An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE will be considered treatment-emergent if the onset date and time is at the time of or after the first study drug administration. The number of participants who experience a TEAE will be reported. |
| Secondary | Number of Participants Who Discontinue Study Due to a TEAE | Up to approximately 7 weeks | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE will be considered treatment-emergent if the onset date and time is at the time of or after the first study drug administration. The number of participants who discontinue study due to a TEAE will be reported. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06625814
GET https://conductscience.org/api/trials/v1/NCT06625814/registered